Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease

By Adria CalatayudRoche Holding said a drug candidate for an autoimmune disease known as IgA nephropathy met the primary goal of a late-stage clinical study, paving the way for the company to seek regulatory approval.The Swiss drugmaker said Wednesday that interim results from a continuing study of…